Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Fused imidazo-pyrazine scaffold derivatives: MerckRecent Research Landscape

Poor bioavailability and manufacturing instability in cardiovascular drug candidates lead to inconsistent therapeutic efficacy. These innovations utilize specific pyrazolopyridine and indazolyl molecular scaffolds to engineer stable, crystallizable compounds that ensure precise cGMP modulation.

What technical problems is Merck addressing in Fused imidazo-pyrazine scaffold derivatives?

Inadequate cyclic nucleotide signaling

(2)evidences

Insufficient cyclic guanosine monophosphate levels lead to pathological vasoconstriction and tissue damage. Restoring signaling homeostasis prevents chronic organ failure.

Insufficient cyclic gmp production

(2)evidences

Amorphous or inconsistent solid states lead to unpredictable solubility and manufacturing instability. Achieving high crystallinity ensures reproducible drug delivery and chemical purity.